Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?

BACKGROUND: SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed. METHODS: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Monin, Malte Benedikt, Gorny, Jens Gabriel, Berger, Moritz, Baier, Leona I., Zhou, Taotao, Mahn, Robert, Sadeghlar, Farsaneh, Möhring, Christian, Boesecke, Christoph, van Bremen, Kahtrin, Rieke, Gereon J., Schlabe, Stefan, Breitschwerdt, Stefan, Marinova, Milka, Schmidt-Wolf, Ingo G. H., Strassburg, Christian P., Eis-Hübinger, Anna-Maria, Gonzalez-Carmona, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331752/
https://www.ncbi.nlm.nih.gov/pubmed/37435197
http://dx.doi.org/10.21037/jgo-22-1065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331752/
https://www.ncbi.nlm.nih.gov/pubmed/37435197
http://dx.doi.org/10.21037/jgo-22-1065

Ejemplares similares